Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | Updated analysis of DESTINY-Gastric02: T-DXd in HER2+ GEJ cancer who progressed with trastuzumab

Geoffrey Ku, MD, Memorial Sloan Kettering Cancer Center, New York, NY, shared the overall-survival and updated efficacy and safety results of the Phase II DESTINY-Gastric02 (NCT04014075) trial exploring trastuzumab deruxtecan (T-DXd) in western patients with HER2-positive (HER2+) unresectable/metastatic gastric/gastroesophageal junction (GEJ) cancer who progressed on or after trastuzumab-containing regimen. The primary endpoint was confirmed objective response rate (cORR). Secondary endpoints included progression-free survival (PFS), duration of response (DOR), OS, and patient-reported outcomes. Primary results demonstrated a cORR of 38.0%. Median duration of follow-up was 10.2 months at data cut-off. Median OS was 12.1 months and 12-month OS rate was 50.6%. cORR was 41.8%. Median DOR was 8.1 months. Median PFS was 5.6 months. Overall, T-DXd continued to show significant clinical benefit and a tolerable safety profile in the treatment of patients with HER2+ unresectable/metastatic gastric/GEJ cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.